Table 1.

Summary of clinical feature of patients with PV treated with idasanutlin with TP53 mutant clones

PatientAge, ySexTime on study, wkNo. of TP53 mutationsClinical responsePrior therapy
68 Female 105.1 PR HU, IFN 
48 Male 85.1 PR IFN 
52 Female 90.9 CR HU 
65 Male 70.1 CR HU 
83 Female 37.1 NR HU 
PatientAge, ySexTime on study, wkNo. of TP53 mutationsClinical responsePrior therapy
68 Female 105.1 PR HU, IFN 
48 Male 85.1 PR IFN 
52 Female 90.9 CR HU 
65 Male 70.1 CR HU 
83 Female 37.1 NR HU 

Clinical responses were assessed by using European LeukemiaNet criteria.

CR, complete response; HU, hydroxyurea; IFN, interferon; NR, no response; PR, partial response.

Close Modal

or Create an Account

Close Modal
Close Modal